Previous studies have demonstrated that the overexpression of TRX in transgenic mice or the administration of recombinant human TRX attenuated focal ischemic brain damage [11], adriamycin-induced cardiotoxicity [12], thioacetamide- or lipopolysaccharide-induced acute hepatitis [13], Helicobacter felis-induced gastritis [14], cerulein- and lipopolysaccharide-induced chronic pancreatitis [15], dextran sulfate sodium (DSS)-induced colitis and colonic inflammation in interleukin (IL)-10 knockout mice [16], and indomethacin-induced gastric mucosal injury [17]. The gene discussed is TXN; the disease is colitis.